CN101757511A - Medicine composition for treating acute and chronic neutrophilic leukemia and preparation method thereof - Google Patents
Medicine composition for treating acute and chronic neutrophilic leukemia and preparation method thereof Download PDFInfo
- Publication number
- CN101757511A CN101757511A CN200810153368A CN200810153368A CN101757511A CN 101757511 A CN101757511 A CN 101757511A CN 200810153368 A CN200810153368 A CN 200810153368A CN 200810153368 A CN200810153368 A CN 200810153368A CN 101757511 A CN101757511 A CN 101757511A
- Authority
- CN
- China
- Prior art keywords
- parts
- leukemia
- radix
- acute
- chronic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a medicine composition for treating acute and chronic neutrophilic leukemia, which is prepared from the following raw medicinal herbs: 10-50 parts of dehydrated dulcite, 30-50 parts of red flower, 30-50 parts of astragalus mongholicus, 15-50 parts of rhizoma sparganii, 15-50 parts of root of red-rooted salvia, 15-50 parts of trogopterus dung and 10-30 parts of radix scrophulariae. The invention has remarkable treatment effect on leukemia, a certain treatment effect on lung cancer, myeloma multiplex, nasopharyngeal darcinoma and the like, better recent treatment effect especially on the acute and chronic neutrophilic leukemia with remission rate of 86 percent, higher effective rate of various lung cancers and lower toxic and side effects.
Description
Technical field
The present invention relates to medical technical field, particularly relate to the leukemic pharmaceutical composition of the treatment that contains dulcitol.
Background technology
Leukemia is a kind of malignant disease of hemopoietic system, and its characteristics are that extensively and uncontrolledly hypertrophy of a large amount of leukaemias is arranged in the body, comes across bone marrow and many other organs and tissue, and enters in the peripheral blood.Acute leukemia is anxious with its onset, progress is fast, the state of an illness is dangerous, the serious harm human health.Along with medical advance, acute leukemia is through active treatment, and most patients can both obtain alleviation, palliating leukemia no longer is the ultimate aim of treatment now, how to improve cure rate, make most of leukemia patients obtain radical cure, become the emphasis of current hematology's research.
Leukemia is one of common tumor, and its sickness rate is about 3-4/10 ten thousand people, and acute more than chronic, acute person accounts for more than 70%, chronic leukemia in China with chronic myelocytic leukemia for seeing more.
Leukemia acute and chronic difference, leukemic acute and chronic notion and the acute and chronic notion (such as acute, chronic hepatitis, acute or chronic gastritis etc.) of other diseases have in essence different.The branch of leukemic acute and chronic, outside the length difference of the speed that the urgency of removing the disease onset is delayed, developed, natural history, key is leukaemia's maturity.Main leukaemia is a germinal cell in acute leukemia bone marrow or the peripheral blood; Mainly be than mature granulocyte or similar sophisticated small lymphocyte in the bone marrow of chronic leukemia and the peripheral blood.Acute leukemic patient though survived in spite of illness several months or several years, still is acute leukemia but not chronic leukemia in essence after treatment.But, the part chronic leukemia, as chronic myelocytic leukemia, can be in a certain stage of the course of disease, the germinal cell in hemogram and the bone marrow is counted showed increased, and the transformation to acute leukemia takes place.Untreated leukaemic, its intravital leukaemia is about 5 * 1010-1013.The patient of Huan Xieing fully, though its leukemic clinical symptoms, sign complete obiteration, it is normal that hemogram and bone marrow smear recover basically, but this moment its body in the still residual leukaemia that a great deal of (108-109 or following) arranged, some hidden part beyond bone marrow still can have leukaemia's infiltration, and these residual leukaemias can cause palindromia.For the remaining leukaemia of further elimination, prevent recurrence, prolong and alleviate and life span, strive for the leukemia healing, still need adopt the treatment of positive consolidation and intensive treatment and even bone marrow transplantation after the alleviation fully.In this case, if can then can avoid or alleviate suchlike toxicity in conjunction with Chinese medicine.Chinese medicine is the traditional medicine of China, and experience precipitation in several thousand makes us can therefrom select the hemopathic medicine of effective treatment.For example, screening is developed from Chinese medicine " treat leukemic pharmaceutical composition " basic prescription is exactly from changing leukaemia's genomic constitution in essence, by the Chinese medicine blood stasis dispelling, purify the blood, set upright, a series of drug regimens such as detoxifcation, effectively suppress leukaemia's proliferate, make it gradually to transform and decompose, simultaneously can also kill the part leukaemia, by strengthening human immunity, improve the human body metabolism, it is external that toxin is got rid of, and implement dialectical treatment acute and chronic lymphoid leukemia in conjunction with patient, all play very significantly specific aim therapeutic effect on the acute and chronic neutrophilic leukemia, can eliminate clinical symptoms rapidly in a short time, improve the state of an illness.Theory of Chinese medical science thinks that the etiology and pathogenesis of malignant hematologic disease is " evil poison ", basic reason is " and the positive deficiency of vital energy ", say with the language of today, be exactly because immunologic hypofunction has caused the generation of malignant hematologic disease under the effect of multiple paathogenic factor in addition.Based on this, Chinese medicine is taked " eliminating evil " and " set upright " two big principles come determination of treatment based on pathogenesis obtained through differentiation of symptoms and signs.
Summary of the invention
The object of the present invention is to provide a kind of pharmaceutical composition of curing chronic myelocytic leukemia.Technology contents of the present invention is implemented by following scheme:
The leukemic pharmaceutical composition of a kind of treatment is characterized in that, said composition is by anhydrous dulcit 10-100 part, and Flos Carthami 30-80 part, Radix Astragali 30-80 part, rhizoma sparganic 15-80 part, Radix Salviae Miltiorrhizae 15-80 part, Oletum Trogopterori 15-50 part, Radix Scrophulariae 10-50 part crude drug are made.
Preferred pharmaceutical composition of the present invention is characterized in that said composition is by anhydrous dulcit 10-80 part, and Flos Carthami 30-50 part, Radix Astragali 30-50 part, rhizoma sparganic 15-50 part, Radix Salviae Miltiorrhizae 15-50 part, Oletum Trogopterori 15-50 part, Radix Scrophulariae 10-30 part crude drug are made.
The pharmaceutical composition that the present invention is more preferably is characterized in that said composition is by anhydrous dulcit 10-50 part, and Flos Carthami 30-40 part, Radix Astragali 30-40 part, rhizoma sparganic 15-30 part, Radix Salviae Miltiorrhizae 15-30 part, Oletum Trogopterori 15-30 part, Radix Scrophulariae 10-20 part crude drug are made.
The particularly preferred pharmaceutical composition of the present invention is characterized in that said composition is by anhydrous dulcit 25-40 part, and Flos Carthami 30-40 part, Radix Astragali 30-40 part, rhizoma sparganic 15-30 part, Radix Salviae Miltiorrhizae 15-30 part, Oletum Trogopterori 25-30 part, Radix Scrophulariae 15-20 part crude drug are made.
The preparation concrete operations of various pharmaceutical preparatioies are as follows:
(1) takes by weighing anhydrous dulcit 25-40 part by the configuration total amount, contain Flos Carthami, the Radix Astragali, rhizoma sparganic, Radix Salviae Miltiorrhizae, Oletum Trogopterori, first conopsea extraction, the filler of adding 40-90%, binding agent, disintegrating agent, lubricant, correctives etc., fully mix and make granule, compacting in 60-70 ℃ of dry 2-4 hour in flakes, maybe with the wet granular made directly at 60-70 ℃ of dry 2-4 hour, be filled into then in the hungry area shell.
(2) composition material adds solvent, the antiseptic of 70-99.5%, fully mixes, and adds activated carbon decolorizing, filters, and uses less than 0.45 μ m microvoid membrane filtration, and embedding after ultrafiltration was sterilized 30-60 minute, and made every ml contain compositions 5-300mg for 100 ℃; Or with gained filtrate by after the standard packing, lyophilized injectable powder is made in lyophilization under vacuum condition.
(3) filler of composition material adding 40%-90%, disintegrating agent, correctives etc. fully mix with the 12-14 mesh sieve and make granule.At 60-70 ℃ of dry 2-4 hour, make every gram granule contain compositions 100-600mg.
Can adopt water, ethanol 30-90% in the preparation method of the present invention is extraction solvent, extracting solution separates again, organic solvent extraction, enrichment, effective ingredient, like this can be, be rich in compositions such as flavonoid, steroidal, polysaccharide and fully extract with the alkaloid of Flos Carthami, the Radix Astragali, rhizoma sparganic, Radix Salviae Miltiorrhizae, Oletum Trogopterori, Radix Scrophulariae.
The present invention can be mixed and made into various preparations with compositions and the excipient substance of making.Pharmaceutic adjuvant of the present invention comprises following excipient: filler: lactose, sucrose, starch, microcrystalline Cellulose, sorbitol, cellulose.Binding agent: gelatin, hydroxypropyl emthylcellulose, polyvinylpyrrolidone, starch, dextrin.Disintegrating agent: microcrystalline Cellulose, carboxymethyl starch sodium, sodium carboxymethyl cellulose, polyvinylpyrrolidone.Lubricant: magnesium stearate; High-molecular bone frame material, for example hydroxypropyl emthylcellulose, hydroxypropyl cellulose, ethyl cellulose, Brazil wax, hydrogenated vegetable oil, acrylic resin.Preparation of pharmaceutical compositions is as follows: use standard and conventional technology; acceptable solid or liquid-carrier are combined, and make it at random to combine and be prepared into microgranule or microsphere with acceptable adjuvant and excipient on the galenic pharmacy.Solid dosage forms comprises tablet, discrete particles, capsule, slow releasing tablet, slow-release micro-pill or the like.Solid carrier can be at least a material, and it can serve as diluent, flavouring agent, solubilizing agent, lubricant, suspending agent, binding agent, disintegrating agent and coating agent.Inert solid carrier comprises magnesium phosphate, magnesium stearate, smoothers sugar, lactose, pectin, propylene glycol, polyoxyethylene sorbitan monoleate, dextrin, starch, gelatin, cellulose substances for example methylcellulose, microcrystalline Cellulose, low melt point paraffin, Polyethylene Glycol, mannitol, cocoa butter etc.Liquid dosage form comprises solvent, suspension for example injection, powder or the like.The amount of the active ingredient that contains in pharmaceutical composition and the unit dosage form (The compounds of this invention) can be according to patient's the state of an illness, specific being applied of situation of diagnosis, the amount of used chemical compound or concentration are regulated in the scope of a broad, usually, the weight range of reactive compound is 0.5%～90% (weight) of compositions, and another preferred range is 0.5%-70%.
The present invention treats leukemic preparation of drug combination method and comprises:
(1) Flos Carthami 30-40 part, Radix Astragali 30-40 part, rhizoma sparganic 15-30 part, Radix Salviae Miltiorrhizae 15-30 part, Oletum Trogopterori 15-30 part, Radix Scrophulariae 10-20 part are mixed, decocting in water 3-10 hour, precipitate with ethanol is removed macromolecular protein, adopts the 70-95% ethanol extraction at every turn, obtains extract.(2) extract and dianhydrodulcitol mix homogeneously are made compositions.
How to prolong the chronic leukemia survival time of patients, the sudden turn of events that reaches the prevention chronic leukemia no longer has been the main target of treatment, finally cures chronic myelocytic leukemia by Drug therapy.Dianhydrodulcitol Dianhydrogalactitol of the present invention and Chinese medicine are mixed and made into compositions, and slow grain leukemia is had short term effect preferably, and remission rate is 86%.Pulmonary carcinoma, multiple myeloma, nasopharyngeal carcinoma etc. also there are certain curative effect, to the effective percentage of various pulmonary carcinoma, only be lower than chlormethine, ametycin and methotrexate, but toxicity are then lighter.Therapeutic Method is as follows: quiet notes or quiet: to slow grain leukemia, and each 40mg that is grown up, the every kg body weight 0.6-1mg of children's, every day 1 time, logotype 5-7 day was 1 course of treatment, drug withdrawal descended for 1 course of treatment after 2 weeks.After the state of an illness was alleviated, every month logotype medicine 5 days was as keeping treatment, preferably keep more than medication half a year for consolidating curative effect, and the dosage 25mg that is grown up every day, the every kg body weight 0.3-0.5mg of children's, to solid carcinomaes such as pulmonary carcinoma, usage and dosage is the same, is spaced apart for 2 weeks the course of treatment; Or symptomatic treatment is treated to descend for 1 course of treatment after hemogram recovers normally again.Compositions is dissolved with isotonic saline solution 10-20mg, slow quiet notes; Or, add 5% xylitol liquid or 5% sodium chloride brine 250-500ml iv drip with after the isotonic saline solution 5ml dissolving.
Be the leukemic pharmaceutical composition three anti-radiation of treatment, leukocyte increasing test below.
1. experiment material:
1.1 animal: purebred C57 mice, body weight 22-24g.
1.1 experimental technique:
1.2.1 grouping and administration: animal is divided into five groups (15/group, male and female half and half) at random: matched group, medicine (compositions) 6mg/kg, 15mg/kg, 30mg/kg, four dosage groups of 60mg/kg.Pre-irradiation continuous 3 administrations in the 3rd, 2,1 days, lumbar injection, 0.5ml/, matched group is given and normal saline, and lumbar injection, 0.5ml/ are only.
1.1.2 the condition of causing injury:
137Cs-gamma-rays one subtotal body irradiation, dosage is respectively: 7.5Gy, close rate be 89.1404 human relations/minute.
Observation index: (1) leukocyte count: irradiation back was taken off vertebra with the mice cervical region on the 9th day and is put to death, and eye socket is got blood, the leukocyte diluted, and ultramicroscope is the numeration cell number down.
(2) dna content, irradiation back took off vertebra with the mice cervical region on the 9th day puts to death, and gets a side femur, normal saline flushing bone marrow.Add reactant liquor, measure absorbance on the ultraviolet spectrophotometer.
(3) CFU-S (Colong forming unit of spleen) puts into BouinShi liquid with spleen, after 24 hours, and the tuberosity number (CFU-S) on the outstanding spleen surface of naked eyes numeration
Experimental result:
Compositions is tested radiation damage mice leukocyte increasing
Learn by statistics and handle, 60mg/Kg group, DNA (OD/ root), WBC * 10
9/ L, the every index of CFU-S is compared significant difference with matched group.
The specific embodiment:
The present invention is described further below in conjunction with embodiment.Embodiment only is to explanation of the present invention, can not be used for limiting the present invention with this.
Embodiment 1
10 parts of anhydrous dulcit, 30 parts on Flos Carthami, 30 parts of the Radixs Astragali, 15 parts of rhizoma sparganic, 15 parts of Radix Salviae Miltiorrhizaes, 15 parts of Oletum Trogopteroris, 10 parts of Radix Scrophulariae, (heating or percolation) 2 times merges 2 times extracting solution, and decompression recycling ethanol gets crude extract, and medicinal residues discard.Crude extract is regulated pH to 7-8 with 5%NaOH liquid, gets alkaline medicinal liquid, with chloroform (or petroleum ether) extraction.Tell the solvent layer, discard, water layer reuse 5% sulphuric acid is transferred pH to 2-4, place, centrifugal, acidic precipitation is standby, get 30g (C) after the drying, solution extracts with chloroform (or petroleum ether), layering, water layer, concentrate 86g, the solvent layer concentrate extract, after the drying 40g (D), with the acidic precipitation mix homogeneously, get mixture 70g.With extract and dianhydrodulcitol mix homogeneously, add 5% glucose saline 250ml iv drip.
Embodiment 2
30 parts on Flos Carthami, 30 parts of the Radixs Astragali, 15 parts of rhizoma sparganic, 15 parts of Radix Salviae Miltiorrhizaes, 15 parts of Oletum Trogopteroris, 10 parts of mixing of Radix Scrophulariae are measured 50% ethanol extractions 2 times with 18 times, merge 2 times extracting solution, decompression recycling ethanol gets crude extract, and medicinal residues discard.Crude extract is regulated pH to 7-8 with 5%NaOH liquid, gets alkaline medicinal liquid, filters, and discards precipitate, supernatant is transferred pH to 2-4 with 5% sulphuric acid, places, and is centrifugal, acidic precipitation is standby, gets 34g after the drying, and solution extracts with ethyl acetate (or n-butyl alcohol), layering, water layer discarded, the solvent layer concentrate extract, get 45g after the drying,, get mixture 79g with the acidic precipitation mix homogeneously, with extract and 10 parts of dianhydrodulcitol mix homogeneously, add 20 parts of starch, 5 parts of mixed pressuring plates of magnesium stearate.
Embodiment 3
80 parts of anhydrous dulcit, 50 parts, 50 parts of the Radixs Astragali, 50 parts of rhizoma sparganic, 50 parts of Radix Salviae Miltiorrhizaes, 50 parts of Oletum Trogopteroris, 30 parts of Radix Scrophulariae mix with 18 times of amount 1% sodium hydroxide (or sodium carbonate) solution extraction 2 times, merge 2 times extracting solution, concentrating under reduced pressure gets crude extract, and medicinal residues discard.Silicagel column on the crude extract with chloroform (or ethyl acetate, methanol) eluting, is collected each several part, carries out qualitative identification with magnesium powder-hydrochloric acid, merges positive part, and concentrating under reduced pressure must mixture 30g.With extract and 10 parts of dianhydrodulcitol mix homogeneously, add No. 2 capsule, make capsule.
Embodiment 4
40 parts of anhydrous dulcit, 40 parts on Flos Carthami, 40 parts of the Radixs Astragali, 30 parts of rhizoma sparganic, 30 parts of Radix Salviae Miltiorrhizaes, 30 parts of Oletum Trogopteroris, 20 parts of Radix Scrophulariae are extracted with 18 times of amount 30% ethanol (heating or percolation), get crude extract, be dissolved in water, solution organic solvent petroleum ether extraction, petroleum ether layer discards, water layer adds ethanol, make the alcohol amount of containing reach 75% ethanol precipitate with ethanol, filter, discard precipitate, supernatant, concentrate and receive alcohol, get extractum, be dissolved in water, with counter-current distribution method continuous extraction 6 hours, aqueous solvent-n-butyl alcohol, extract concentrate mixture 55g, with extract and 40 parts of dianhydrodulcitol mix homogeneously, evaporate to dryness adds 5% glucose saline and makes injection for 100 parts.
Claims (5)
1. pharmaceutical composition for the treatment of acute and chronic neutrophilic leukemia, it is characterized in that, said composition is by anhydrous dulcit 10-100 part, and Flos Carthami 30-80 part, Radix Astragali 30-80 part, rhizoma sparganic 15-80 part, Radix Salviae Miltiorrhizae 15-80 part, Oletum Trogopterori 15-50 part, Radix Scrophulariae 10-50 part crude drug are made.
2. pharmaceutical composition as claimed in claim 1, it is characterized in that said composition is by anhydrous dulcit 10-80 part, Flos Carthami 30-50 part, Radix Astragali 30-50 part, rhizoma sparganic 15-50 part, Radix Salviae Miltiorrhizae 15-50 part, Oletum Trogopterori 15-50 part, Radix Scrophulariae 10-30 part crude drug are made.
3. pharmaceutical composition as claimed in claim 1, it is characterized in that said composition is by anhydrous dulcit 10-50 part, Flos Carthami 30-40 part, Radix Astragali 30-40 part, rhizoma sparganic 15-30 part, Radix Salviae Miltiorrhizae 15-30 part, Oletum Trogopterori 15-30 part, Radix Scrophulariae 10-20 part crude drug are made.
4. pharmaceutical composition as claimed in claim 1, it is characterized in that said composition is by anhydrous dulcit 25-40 part, Flos Carthami 30-40 part, Radix Astragali 30-40 part, rhizoma sparganic 15-30 part, Radix Salviae Miltiorrhizae 15-30 part, Oletum Trogopterori 25-30 part, Radix Scrophulariae 15-20 part crude drug are made.
5. described compositions of claim 1-4 and excipient substance are mixed and made into various preparations.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200810153368A CN101757511A (en) | 2008-11-25 | 2008-11-25 | Medicine composition for treating acute and chronic neutrophilic leukemia and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200810153368A CN101757511A (en) | 2008-11-25 | 2008-11-25 | Medicine composition for treating acute and chronic neutrophilic leukemia and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101757511A true CN101757511A (en) | 2010-06-30 |
Family
ID=42488995
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200810153368A Pending CN101757511A (en) | 2008-11-25 | 2008-11-25 | Medicine composition for treating acute and chronic neutrophilic leukemia and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101757511A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105362886A (en) * | 2015-12-02 | 2016-03-02 | 钊桂英 | Preparation for treating acute leukemia and preparation method |
| CN105797025A (en) * | 2016-04-15 | 2016-07-27 | 宁波优美科新材料有限公司 | Medicine for treating chronic granulocytic leukemia |
-
2008
- 2008-11-25 CN CN200810153368A patent/CN101757511A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105362886A (en) * | 2015-12-02 | 2016-03-02 | 钊桂英 | Preparation for treating acute leukemia and preparation method |
| CN105797025A (en) * | 2016-04-15 | 2016-07-27 | 宁波优美科新材料有限公司 | Medicine for treating chronic granulocytic leukemia |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102846866A (en) | Chinese medicine composition for prevention and control of porcine circovirus disease and preparation method thereof | |
| CN101904974B (en) | Chinese medicinal composition for treating malignant tumor diseases and preparation method thereof | |
| CN102247479B (en) | Antitumor strong medicine and preparation method thereof | |
| CN104069344A (en) | Traditional Chinese medicine composition for treating cancer and preparation and preparation method thereof | |
| CN101757511A (en) | Medicine composition for treating acute and chronic neutrophilic leukemia and preparation method thereof | |
| CN100464759C (en) | Anticancer Chinese traditional extracts and preparation process and application thereof | |
| CN1686423A (en) | Medicinal composition containing scutellaria glucoside and bupleurum and its preparation method | |
| CN102389496A (en) | Chinese medical composition for treating hepatitis and preparation method thereof | |
| CN101444572A (en) | Pharmaceutical composition for treating leukaemia | |
| CN101411779A (en) | Chinese medicine effective component composition for treating liver cancer and method for preparing the same | |
| CN101919919B (en) | Fukean dispersible tablet and preparation method thereof | |
| CN1139565A (en) | Nourishing medicine for preventing and curing toxic and side effect after tumor radiotherapy and chemotherapy and preparation method | |
| CN105727089A (en) | Application of medicine composition containing folium artemisiae argyi to preparing medicine for treating irritable bowel syndrome | |
| CN102058668A (en) | Traditional Chinese medicinal preparation for treating primary thrombocytopenia | |
| CN101450143A (en) | Medicine composition for treating leukemia | |
| CN104998085A (en) | Chinese herbal compound composition capable of enhancing immune function and preparation method thereof | |
| CN101450100A (en) | Medicine composition for treating urgent and chronic myelocytic leukemiaia | |
| CN101850009B (en) | Jinwei calculus-eliminating preparation and preparation method thereof | |
| CN101214325B (en) | Method for preparing compound 'chenxiangwei'medicine and new use thereof | |
| CN101549140B (en) | Traditional Chinese medicine composition for treating AIDS and preparation method thereof | |
| CN1827138A (en) | Chinese medicine composition prescription for treating cardiovascular and cerebrovascular diseases and preparation technique thereof | |
| CN100536883C (en) | Use of konjak and its extract in preparation of medicine for treating acute and chronic bronchitis | |
| CN108403906A (en) | A kind of pharmaceutical composition and preparation method thereof of prevention rheumatoid arthritis | |
| CN101757302A (en) | Medicament composition for treating leukemia | |
| CN101347446B (en) | Medicament composition containing astragalus polysaccharide and ginseng bud saponin and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20100630 |